• Svetomir N Markovic, Lori A Erickson, Ravi D Rao, Roger H Weenig, Barbara A Pockaj, Aditya Bardia, Celine M Vachon, Steven E Schild, Robert R McWilliams, Jennifer L Hand, Susan D Laman, Lisa A Kottschade, William J Maples, Mark R Pittelkow, Jose S Pulido, J Douglas Cameron, Edward T Creagan, and Melanoma Study Group of Mayo Clinic Cancer Center.
• Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
• Mayo Clin. Proc. 2007 Apr 1; 82 (4): 490-513.

AbstractCritical to the clinical management of a patient with malignant melanoma is an understanding of its natural history. As with most malignant disorders, prognosis is highly dependent on the clinical stage (extent of tumor burden) at the time of diagnosis. The patient's clinical stage at diagnosis dictates selection of therapy. We review the state of the art in melanoma staging, prognosis, and therapy. Substantial progress has been made in this regard during the past 2 decades. This progress is primarily reflected in the development of sentinel lymph node biopsies as a means of reducing the morbidity associated with regional lymph node dissection, increased understanding of the role of neoangiogenesis in the natural history of melanoma and its potential as a treatment target, and emergence of innovative multimodal therapeutic strategies, resulting in significant objective response rates in a disease commonly believed to be drug resistant. Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach.

12 keywords...

hide…